Multi-Site Clinical Evaluation of DW-MRI as a Treatment Response Metric for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Fig 5
Evaluation of PRMADC as a response metric.
Parametric response maps (A) and (C) and corresponding scatter plots (B) and (D) of post- versus pre-treatment ADC values are presented for a representative non-responder (top row) and responder (bottom row). The joint density histogram from the non-responder demonstrated a negligible shift resulting in a PRMADC+, i.e., the relative tumor volume with significantly increasing ADC values, of 1.8%. In contrast, a substantial shift in the histogram was observed for the responder (PRMADC+ of 12.8%).